Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

NCT05429918 · clinicaltrials.gov ↗

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Sponsor

Peking University Third Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]